REGN
REGN
US75886F1075
Regeneron Pharmaceuticals, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 14.342.900.000 14.202.000.000
1.0%
Cost of Revenue 2.100.700.000 1.970.500.000
6.6%
Gross Profit 12.242.200.000 12.231.500.000
0.1%
8.540.200.000 8.240.800.000
3.6%
Operating Income 3.702.000.000 3.990.700.000
7.2%
Pretax Income 5.230.700.000 4.779.900.000
9.4%
Net Income Common Stockholders 4.504.900.000 4.412.600.000
2.1%
-- --
--
-- --
--
ende